Clinical trial
A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid…
NCT00139620 · OSI Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00139620 |
|---|---|
| Title | A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function |
| Official title | An Open-Label Study to Characterize the Pharmacokinetic Parameters of Erlotinib (Tarceva®, OSI-774) in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function |
| Lead sponsor | OSI Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Solid Tumors |
| Intervention type | Drug |
| Interventions | Tarceva, erlotinib, OSI-774 |
| Enrollment | 39 |
| Start date | Aug 22, 2005 |
| Primary completion | Jun 25, 2007 |
| Completion | Jun 25, 2007 |
| First posted | Aug 31, 2005 |
| Last update posted | Feb 8, 2018 |
| Countries | United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: